8-KMaterial Agreements

DEXCOM INC 8-K Report, Material Agreement (Jan 13, 2009)

Filed January 13, 2009For Securities:DXCM

Summary

DexCom, Inc. (DXCM) announced on January 13, 2009, a significant update to its strategic partnership with Animas Corporation, a key player in the insulin pump market. The company has entered into Amended and Restated Joint Development and OUS Commercialization Agreements, which significantly reshape their collaboration concerning DexCom's continuous glucose monitoring (CGM) technology. These revised agreements grant Animas exclusive rights to develop and market CGM-enabled insulin pumps outside the United States, with a non-exclusive right to do so domestically. This strategic move is expected to expand the global reach of DexCom's CGM technology through Animas' established distribution channels. The financial terms include a $5 million milestone payment from Animas upon the first international regulatory approval for the integrated system, along with a $300,000 contribution to DexCom's development costs. Additionally, DexCom will receive a royalty of $200 per integrated pump sold internationally, highlighting the revenue potential of this partnership.

Key Highlights

  • 1DexCom entered into Amended and Restated Joint Development and OUS Commercialization Agreements with Animas Corporation.
  • 2Animas gains exclusive rights to develop and market CGM-enabled insulin pumps outside the United States.
  • 3Animas retains non-exclusive rights to develop and market CGM-enabled insulin pumps within the United States.
  • 4Animas will pay DexCom a $5 million milestone payment upon first international regulatory approval for the new system.
  • 5Animas will contribute $300,000 towards DexCom's development expenses.
  • 6DexCom will receive a royalty of $200 for each CGM-enabled pump sold outside the United States.
  • 7The agreements have an initial term of three years, with automatic renewal provisions.

Frequently Asked Questions

The primary purpose is to expand the commercialization of DexCom's continuous glucose monitoring (CGM) technology by integrating it with Animas' insulin pumps, particularly for the international market, while also refining the terms of their joint development efforts.

DexCom is set to receive a $5 million milestone payment upon international regulatory approval, a $300,000 contribution to development costs, and a $200 royalty for each integrated CGM-enabled pump sold outside the U.S.

Animas Corporation will exclusively develop and market CGM-enabled insulin pumps outside the U.S. and non-exclusively within the U.S. They will also distribute DexCom's sensors and transmitters for use in these integrated systems.

The initial term for both the Joint Development Agreement and the OUS Commercialization Agreement is three years from their respective effective dates, with automatic renewal unless either party opts out.